Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E15.51 EPS (ttm)5.28 Insider Own0.10% Shs Outstand716.10M Perf Week-6.47%
Market Cap58.60B Forward P/E7.70 EPS next Y10.63 Insider Trans-5.48% Shs Float700.67M Perf Month-6.13%
Income4.07B PEG0.79 EPS next Q2.23 Inst Own76.50% Short Float1.46% Perf Quarter-4.68%
Sales14.12B P/S4.15 EPS this Y109.10% Inst Trans0.31% Short Ratio2.16 Perf Half Y-10.18%
Book/sh4.79 P/B17.08 EPS next Y21.09% ROA8.60% Target Price111.65 Perf Year-40.03%
Cash/sh4.76 P/C17.18 EPS next 5Y19.62% ROE44.10% 52W Range74.13 - 139.72 Perf YTD-21.59%
Dividend- P/FCF17.41 EPS past 5Y25.80% ROI20.00% 52W High-41.43% Beta1.39
Dividend %- Quick Ratio1.40 Sales past 5Y18.70% Gross Margin96.50% 52W Low10.39% ATR2.11
Employees7467 Current Ratio1.50 Sales Q/Q-38.80% Oper. Margin28.20% RSI (14)33.01 Volatility2.92% 2.20%
OptionableYes Debt/Eq6.20 EPS Q/Q-42.90% Profit Margin19.80% Rel Volume0.66 Prev Close82.58
ShortableYes LT Debt/Eq5.76 EarningsOct 25 BMO Payout0.00% Avg Volume4.74M Price81.83
Recom2.20 SMA20-6.57% SMA50-8.53% SMA200-8.15% Volume3,132,691 Change-0.91%
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-15-18 05:45PM  Celgene (CELG) Dips More Than Broader Markets: What You Should Know Zacks
Oct-12-18 08:21AM  5 Stocks to Absolutely Love During This Correction Motley Fool
Oct-11-18 01:41PM  Here's Why bluebird bio Dropped 13.3% in September Motley Fool
07:30AM  Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy Business Wire
Oct-10-18 07:20PM  Top 3 Healthcare Stocks for 2018 Investopedia
10:18AM  Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status Zacks
07:35AM  BRIEF-Beigene Announces National Reimbursement Inclusion Of Vidaza® (Azacitidine For Injection) By The State Medical Insurance Administration In China Reuters
07:30AM  New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018 Business Wire
Oct-09-18 10:44PM  [$$] The Menendez Method The Wall Street Journal
08:45PM  [$$] The Menendez Method The Wall Street Journal
04:35PM  Better Buy: Crispr Therapeutics AG vs. Editas Motley Fool
08:32AM  Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study Zacks
08:03AM  The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial Benzinga
Oct-08-18 04:37PM  Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint Business Wire
Oct-05-18 06:14PM  Celgene (CELG) Dips More Than Broader Markets: What You Should Know Zacks
Oct-04-18 08:51AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Oct-03-18 07:33PM  Top 5 Biotech Stocks for 2018 Investopedia
Oct-02-18 12:00PM  Cantor Fitzgerald Starts Coverage of Health Care Stocks GuruFocus.com
11:00AM  2 Stocks That Can Safely Double Your Money Motley Fool
Oct-01-18 07:30AM  Celgene Corporation to Announce Third Quarter 2018 Results on October 25, 2018 Business Wire
Sep-29-18 07:15AM  2 Stocks That Could Benefit Big From Geron's Stumble Motley Fool
Sep-28-18 10:06AM  3 Biotech Stocks With Rising Estimates in the Past Month Zacks
09:59AM  Zacks Value Trader Highlights: Celgene, Beazer Homes, Graftech, MoneyGram and Turtle Zacks
Sep-27-18 05:45PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
05:43PM  How the latest biotech IPO targets faster, better drug development American City Business Journals
08:25AM  Report: Exploring Fundamental Drivers Behind Ryanair, Ctrip.com International, CyrusOne, Fabrinet, Celgene, and AT&T New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:41AM  The Zacks Analyst Blog Highlights: Amazon, Intel, Merck, Micron and Celgene Zacks
Sep-25-18 06:05PM  Alexion's Soliris Successful in Phase III Study for NMOSD Zacks
08:29AM  Trump Clinches Trade Deal With South Korea: 6 Winning Picks Zacks
Sep-24-18 12:41PM  Here's Why AnaptysBio Inc Rose as Much as 18.5% Today Motley Fool
Sep-23-18 06:33AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Sep-21-18 07:12AM  Top 5 ROE Picks as Markets Shrug Off Heightened Trade Fears Zacks
Sep-20-18 05:45PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
03:12PM  The 7 Best Biotech Stocks for Investors Who Hate Risk Kiplinger
07:32AM  The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences Zacks
Sep-19-18 06:03PM  Bristol-Myers' MM Drug Empliciti Application Validated by EMA Zacks
02:38PM  7 Biotech Stocks to Buy Now InvestorPlace
11:01AM  Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success Zacks
06:00AM  Biotech Celgene Seen Rebounding 10% on Higher Sales Investopedia
Sep-17-18 10:09AM  Better Buy: Celgene Corp. vs. Biogen Motley Fool
Sep-14-18 10:15AM  Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory Motley Fool
09:09AM  The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion Zacks
Sep-13-18 09:14AM  IPOs and Foreign Investment Propel Biotech: 4 Top Picks Zacks
07:41AM  Zacks.com featured highlights include: Nucor, PCM, Celgene and Rayonier Zacks
Sep-12-18 05:45PM  Celgene (CELG) Stock Sinks As Market Gains: What You Should Know Zacks
11:28AM  Menendez Hammers Senate Opponent on Celgene Drugs Bloomberg
10:30AM  Immuno Oncology & Targeted Therapy Companies Set to Breakout ACCESSWIRE
07:30AM  OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone Business Wire
Sep-11-18 11:37AM  Endocyte Announces FDA's Acceptance of Trial Endpoint Change Zacks
Sep-08-18 08:15AM  Is Now a Good Time to Buy Celgene? Motley Fool
Sep-07-18 09:15AM  Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete -- Here's Why That's Great for Investors Motley Fool
Sep-06-18 03:36PM  bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy Zacks
Sep-05-18 05:34PM  Horizon Pharma Completes Enrollment in Eye Disease Study Zacks
05:15PM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
04:40PM  Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout Zacks
10:21AM  Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position Zacks
Sep-04-18 06:33PM  Agios names former Celgene executive Jacqualyn Fouse as next CEO Reuters
06:12PM  Agios names former Celgene executive Jacqualyn Fouse as next CEO Reuters
03:17PM  Here's Why Acceleron Pharma Rose 24% in August Motley Fool
09:56AM  Top 5 ROE Picks as Trade Dispute With China & Canada Lingers Zacks
Sep-03-18 05:45PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
Sep-02-18 09:00AM  Juno Therapeutics and investors reach settlement related to fatal drug trial American City Business Journals
Aug-31-18 05:35PM  Biotech Fund Flows, Including ETF Activity, Remain a Driver to Watch ETF Trends
04:19PM  Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A Zacks
Aug-30-18 10:41AM  Biotech baker's dozen: Peninsula stalwart seeks Bay Area's 13th life sciences IPO this year American City Business Journals
09:50AM  Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data Zacks
08:03AM  3 Big Stock Charts for Thursday: Tiffany & Co., Celgene and Oneok InvestorPlace
Aug-29-18 02:00PM  3 Stocks That May Lead a Massive Biotech Breakout Investopedia
11:52AM  5 Healthcare Stocks That Are Down, But Not Out! InvestorPlace
09:14AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
08:28AM  Trade of the Day: Celgene Is Coiling Up for a Rally InvestorPlace
06:02AM  Is Celgene Corporation a Buy? Motley Fool
Aug-28-18 05:45PM  Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval Zacks
02:49PM  Nasdaq Crosses 8,000 Mark: Play 5 Top-Ranked Stocks InvestorPlace
Aug-27-18 05:53PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
03:05PM  New Strong Buy Stocks for August 27th InvestorPlace
12:14PM  Play The Future of Gene Therapy With These 5 Biotech Stocks InvestorPlace
10:44AM  New Strong Buy Stocks for August 27th Zacks
08:13AM  The Zacks Analyst Blog Highlights: Amazon, Microsoft, Apple, Bristol-Myers and Celgene Zacks
Aug-24-18 12:37PM  As S&P 500 hits record highs, one-fifth of its stocks are still in a bear market CNBC
09:51AM  R&D Spending Hits the Fastest Pace in 12 Years: Top 5 Winners Zacks
09:41AM  Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema Zacks
08:16AM  3 Relatively Safe Ways to Invest in Gene Editing Motley Fool
Aug-23-18 09:18AM  4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings Zacks
09:10AM  Mallinckrodt's Stannsoporfin Gets Complete Response Letter Zacks
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conferences Business Wire
Aug-22-18 04:07PM  Alnylam Completes Enrollment in Phase III Givosiran Study Zacks
02:43PM  Should You Be Worried When Celgene Corporations (NASDAQ:CELG) Insiders Sell? Simply Wall St.
12:17PM  Senate race in blue New Jersey tightens as ethics issues dog Democrat Bob Menendez, poll says CNBC
08:55AM  Infinity Focuses on Developing IPI-549 for Solid Tumors Zacks
Aug-21-18 05:38PM  Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC Zacks
05:08PM  Is Celgene Set to See Improved Results in the Second Half? Zacks
10:41AM  5 Low-Cost Biotech Stocks With High Levels of Growth InvestorPlace
Aug-20-18 04:47PM  Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin Zacks
10:03AM  8 Undervalued Biotech Stocks to Watch InvestorPlace
08:26AM  Better Buy: Celgene Corporation vs. Bristol-Myers Squibb Motley Fool
07:52AM  Top 5 ROE Picks on Optimism Over Resolution of Trade Dispute Zacks
06:00AM  Celgene's Stock May See More Big Gains Ahead Investopedia
Aug-16-18 08:48AM  10 Roughed-Up Stocks to Buy for a Recovery Rally Kiplinger
07:00AM  Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musks Tail Market Exclusive
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM
Smith Scott AndrewSee RemarksFeb 17Option Exercise0.007,283051,748Feb 20 05:03 PM
KELLOGG PETER NSee RemarksFeb 17Option Exercise0.007,283049,660Feb 20 05:03 PM
Alles Mark JSee RemarksFeb 17Option Exercise0.007,2830186,187Feb 20 05:00 PM
KAPLAN GILLADirectorFeb 15Option Exercise27.189,250251,41594,801Feb 20 05:02 PM
KAPLAN GILLADirectorFeb 15Sale95.999,250887,89885,551Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM